<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="20118"><DrugName>gene therapy (xenograft), BioTransplant</DrugName><DrugNamesKey><Name id="42788892">XenoMune</Name></DrugNamesKey><DrugSynonyms><Name><Value>XenoMune</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>gene therapy (xenograft), BioTransplant</Value></Name></DrugSynonyms><CompanyOriginator id="14847">BioTransplant Inc</CompanyOriginator><CompaniesSecondary><Company id="14847">BioTransplant Inc</Company><Company id="21569">Massachusetts General Hospital</Company><Company id="23137">Novartis AG</Company><Company id="24839">Harvard Medical School</Company></CompaniesSecondary><CrossReferences><SourceEntity id="20118" type="Drug"><TargetEntity id="303522" type="siDrug">XenoMune System</TargetEntity></SourceEntity><SourceEntity id="14847" type="Company"><TargetEntity id="4295905730" type="organizationId">Biotransplant Inc</TargetEntity></SourceEntity><SourceEntity id="21569" type="Company"><TargetEntity id="4296541778" type="organizationId">Massachusetts Gen Hosp Pooled Pnsin Tr</TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="24839" type="Company"><TargetEntity id="4296615285" type="organizationId">Harvard Medical School</TargetEntity></SourceEntity><SourceEntity id="515" type="ciIndication"><TargetEntity id="10044439" type="MEDDRA"></TargetEntity><TargetEntity id="D006084" type="MeSH"></TargetEntity><TargetEntity id="1133" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="515">Transplant rejection</Indication></IndicationsSecondary><ActionsSecondary><Action id="4792">Unspecified vector based gene therapy</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2017-08-30T10:09:55.000Z</LastModificationDate><ChangeDateLast>2009-01-13T14:25:45.000Z</ChangeDateLast><AddedDate>1998-10-05T15:15:19.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;BioTransplant was investigating products for the prevention of xenograft rejection in collaboration with &lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt;, &lt;ulink linkID="21569" linkType="Company"&gt;Massachusetts General Hospital&lt;/ulink&gt; and &lt;ulink linkID="24839" linkType="Company"&gt;Harvard Medical School&lt;/ulink&gt; [&lt;ulink linkID="300406" linkType="reference"&gt;300406&lt;/ulink&gt;]. However, no further development has been reported by &lt;ulink linkID="24839" linkType="Company"&gt;Harvard Medical School&lt;/ulink&gt; since September 1998 [&lt;ulink linkID="300406" linkType="reference"&gt;300406&lt;/ulink&gt;], and &lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt; and &lt;ulink linkID="21569" linkType="Company"&gt;Massachusetts General Hospital&lt;/ulink&gt; have reported no further development since March 2000 [&lt;ulink linkID="360570" linkType="reference"&gt;360570&lt;/ulink&gt;]. In February 2003, BioTransplant filed voluntary petitions for reorganization under Chapter 11 of the US Bankruptcy Code [&lt;ulink linkID="480211" linkType="reference"&gt;480211&lt;/ulink&gt;], and in November 2003, reported that it had no active operations [&lt;ulink linkID="514608" linkType="reference"&gt;514608&lt;/ulink&gt;]. BioTransplant's Xenomune development program was assumed to have been discontinued by this time.&lt;/para&gt;&lt;para&gt;In September 1998, BioTransplant's collaborators at the &lt;ulink linkID="21569" linkType="Company"&gt;Massachusetts General Hospital&lt;/ulink&gt; and &lt;ulink linkID="24839" linkType="Company"&gt;Harvard Medical School&lt;/ulink&gt; announced that they used a gene therapy product to specifically block the immune response that leads to antibody-mediated hyperacute xenograft rejection (HAR) in mice [&lt;ulink linkID="300406" linkType="reference"&gt;300406&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The XenoMune system, for the transplantation of organs from miniature swine into humans, contains many different approaches designed to facilitate the acceptance of donor tissue by the human immune system [&lt;ulink linkID="300406" linkType="reference"&gt;300406&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;ImmunoCognance is BioTransplant's technology that is designed to allow the recipient's immune system to accept donor tissue as its own without compromising the recipient's immune system [&lt;ulink linkID="300406" linkType="reference"&gt;300406&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="14847">BioTransplant Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="515">Transplant rejection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-11-24T00:00:00.000Z</StatusDate><Source id="514608" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24839">Harvard Medical School</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-03-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21569">Massachusetts General Hospital</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-09-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-09-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14847">BioTransplant Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-10-05T00:00:00.000Z</StatusDate><Source id="300406" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-03-23T00:00:00.000Z</StatusDate><Source id="360570" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24839">Harvard Medical School</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-10-05T00:00:00.000Z</StatusDate><Source id="300406" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21569">Massachusetts General Hospital</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-10-05T00:00:00.000Z</StatusDate><Source id="300406" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="14847">BioTransplant Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="23137">Novartis AG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="24839">Harvard Medical School</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="10">Technology - Other Proprietary</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><Deals><Deal id="119328" title="The Harvard Medical School to collaborate with BioTransplant on its Xenomune program "></Deal><Deal id="119329" title="Massachusetts General Hospital to collaborate with BioTransplant on its Xenomune program"></Deal><Deal id="119342" title="Novartis to collaborate on BioTransplant's mixed bone marrow chimerism technology for transplant rejection worldwide "></Deal></Deals><PatentFamilies><PatentFamily id="1059881" number="WO-09638178" title="Allogeneic and xenogeneic transplantation."></PatentFamily><PatentFamily id="1134068" number="WO-09524913" title="Treatment Of Graft-Versus-Host Disease"></PatentFamily><PatentFamily id="1164897" number="WO-09528412" title="alpha(1,3) Galactosyltransferase negative swine."></PatentFamily><PatentFamily id="1311904" number="WO-09513363" title="Hematopoietic stem cells from swine cord blood and uses thereof."></PatentFamily><PatentFamily id="1460815" number="WO-09706241" title="Transgenic swine and swine cells having human HLA genes."></PatentFamily><PatentFamily id="1504043" number="WO-09426285" title="Xenograft Thymus"></PatentFamily><PatentFamily id="1537814" number="WO-09606642" title="Allogeneic and xenogeneic transplantation."></PatentFamily><PatentFamily id="1725284" number="AU-05668899" title="Depletion Of Cells Responsible For Antibody-Mediated Graft Rejection"></PatentFamily><PatentFamily id="1800391" number="WO-00011187" title="Molecular Sequence Of Swine Retrovirus And Methods Of Use"></PatentFamily><PatentFamily id="1903649" number="WO-09833528" title="Induction of B cell tolerance."></PatentFamily><PatentFamily id="197786" number="WO-00125398" title="Process For Inducing Functional Tolerance To Gene Transfer Products"></PatentFamily><PatentFamily id="1980128" number="WO-00187310" title="Process for reducing antibody response against xenografts"></PatentFamily><PatentFamily id="199736" number="WO-09112849" title="Engrafting Allogeneic Tissues Or Organs Using Interleukin"></PatentFamily><PatentFamily id="2211030" number="EP-00699073" title="Xenogeneic transplantation"></PatentFamily><PatentFamily id="2244125" number="WO-09606165" title="Genetically engineered swine cells."></PatentFamily><PatentFamily id="23303" number="WO-09506657" title="Interleukin-10 and immunosuppression."></PatentFamily><PatentFamily id="347886" number="WO-09707823" title="Compositions and their uses."></PatentFamily><PatentFamily id="468234" number="WO-00011147" title="Inbred Mhc-Homozygous Miniature Swine And Uses Thereof"></PatentFamily><PatentFamily id="56361" number="WO-09309815" title="Specific tolerance in transplantation."></PatentFamily><PatentFamily id="911544" number="WO-09521527" title="Stem cell engraftment."></PatentFamily><PatentFamily id="943451" number="WO-09313785" title="Induced tolerance to xenografts."></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>14</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="14">Tentative</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>7</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BioTransplant Inc" id="14847"></CompanyLink><CountAsOwner>20</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>21</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="US Government" id="20516"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"></CompanyLink><CountAsOwner>9</CountAsOwner><CountAsThirdParty>7</CountAsThirdParty><CountTotal>16</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvard Medical School" id="24839"></CompanyLink><CountAsOwner>13</CountAsOwner><CountAsThirdParty>3</CountAsThirdParty><CountTotal>16</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>